NCT03203473 2026-02-06
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Dana-Farber Cancer Institute
AstraZeneca
Medtronic - MITG
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)